背景介绍 B7-2 (CD86) signaling through CTLA4 (CD152) has been shown to inhibit T- cell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancers to escape the host's immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy) and Tremelimumab, have shown clinical efficacy in treating cancer. 产品介绍 The CTLA4:B7-2[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of CTLA4:B7-2-biotin interaction. The key to this kit is the high sensitivity of detection of CTLA4 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, CTLA4 is coated on a 96-well plate. Next, B7-2-biotin is incubated with CTLA4 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.